The tyrosine kinase inhibitor Imatinib Mesylate has dramatically improved the clinical
outcome of chronic myeloid leukemia (CML) patients in the chronic phase of the disease …

Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even
undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication of the disease …

The availability of several BCR-ABL1 tyrosine kinase inhibitor (TKI) options means
physicians and patients can select the most appropriate treatment for a patient with chronic …

In this paper, based on Plastoquinone (PQ) analogs possessing substituted aniline
containing alkoxy group (s), new 2, 3-dimethyl-5-amino-1, 4-benzoquinones (PQ1-15) were …

Background Imatinib treatment often produces various adverse reactions in patients with
chronic myeloid leukemia (CML), and increasing patients are pursuing dose optimization. In …

The development of BCR/ABL1 tyrosine kinase inhibitors (TKIs) over the past 20 years has
dramatically improved the outcomes for patients with every stage of Philadelphia …

In the past decade, numerous tyrosine kinase inhibitors (TKIs) have been introduced in the
treatment of chronic myeloid leukemia. Given the significant interpatient variability in TKIs …

The concept of hybrid drugs for targeting multiple aberrant pathways of cancer, by
combining the key pharmacophores of clinically approved single-targeted drugs, has …

Chronic myeloid leukemia was the first haematological neoplasia that benefited from a
targeted therapy with imatinib nearly 15 years ago. Since then, several studies have …

The efficacy of second‐line treatment for chronic myeloid leukemia (CML) plays an important
role in allowing CML patients to enjoy a normal life expectancy. Four tyrosine kinase …